PET scans probe link between brain inflammation and Alzheimer's damage

NCT ID NCT05911178

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study uses advanced PET scans to investigate how brain inflammation and tau protein buildup affect synaptic density in people with Alzheimer's disease. Researchers will compare Alzheimer's patients to healthy controls over two years, tracking changes in these brain markers. The goal is to better understand the disease's progression and refine patient subgroups for future treatment trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PET tracers ([11C]-UCB-J, [18F]-DPA-714, [18F]-RO-948, [11C]-PiB) used for brain imaging
What this could lead to
Could help identify distinct Alzheimer's subtypes based on brain inflammation and tau patterns, leading to more targeted treatments.
What could go wrong
This is an observational imaging study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all Alzheimer's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Oct 2023

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General Inclusion Criteria: * Adult (older than 18 years) * Women old enough to procreate under effective contraception * Signed consent * Absence of general or systemic disorders that may interfere with cognition. Inclusion criteria for EOAD and LOAD patients: * Progressive amnestic syndrome, associated or not with other cognitive impairments, * CDR = 0.5 or 1 * Absence of general or systemic disorders that may interfere with cognition or PET imaging analysis, * Absence of brain lesions as determined by MRI carried out within the framework of usual care. * Presence of CSF biomarkers profile suggestive of AD Inclusion criteria for controls: * absence of subjective problems with memory and normal scores on the MMSE (MMSE \> 27) with no more than one word missing. * older than 50 years old. * Scores on the Free and Cued Selective Reminding Test (FCSRT) of \>25 for free recall and \>44 for total recall. * absence of general or systemic disorders that may interfere with cognition at follow-up. Controls will be matched to AD patients for age and education level. Exclusion Criteria: * Subject with a psychiatric evolutionary and/or poorly checked pathology (left to the judgement of the investigator). * Subject with a grave, severe or unstable pathology (left to the judgement of the investigator) the nature of which can interfere with the variables of evaluation. * Current auto-immune disease * Subject presenting contraindications to the 3T MRI * Known or supposed histories (≤5 years) of severe alcoholism or misuse of drugs * Vascular, inflammatory or expansive, visible lesion in the MRI which can interfere on the criteria of diagnosis. * No health insurance * Pregnant, breast-feeding woman or planning a pregnancy in two years of follow-up. * Diagnosis or history of other possible etiology of dementia, including but not limited to other neurodegenerative disorders. * Person placed under the protection of justice * Patient under guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Neuroinflammatory Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Lille

    Lille, France

  • CHU de Rouen

    Rouen, France

  • GHU Saint Anne Psychiatrie & Neurosciences

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.